TORONTO--(BUSINESS WIRE)--
Jamieson Wellness Inc. (“Jamieson Wellness” or the “Company”) (TSX:
JWEL) today reported financial results for its fourth quarter and twelve
months ended December 31, 2018. All amounts are expressed in Canadian
dollars. Certain metrics, including those expressed on an adjusted
basis, are non-IFRS measures. See “Non-IFRS Financial Measures” below.
Highlights of Fourth Quarter 2018 Results versus Fourth Quarter 2017
Results
-
Revenue increased 18% to $99.1 million (see note on “IFRS 15 – Revenue
Recognition” below);
-
Revenue increased 22% to $102.8 million excluding the new revenue
recognition accounting impact;
-
Adjusted EBITDA increased 22% to $22.9 million;
-
Net Income was $10.0 million and Adjusted Net Income increased 25% to
$12.2 million;
-
Earnings per Diluted Share were $0.25, and Adjusted Earnings per
Diluted Share increased 24% to $0.31.
Highlights of Full Year 2018 Results versus Full Year 2017 Results
-
Revenue increased 6% to $319.8 million (see note on “IFRS 15 – Revenue
Recognition” below);
-
Revenue increased 11% to $333.1 million excluding the new revenue
recognition accounting impact;
-
Adjusted EBITDA increased 10% to $67.6 million;
-
Net income was $26.7 million and Adjusted Net Income increased 22% to
$33.7 million;
-
Earnings per Diluted Share were $0.67, and Adjusted Earnings per
Diluted Share increased 21% to $0.85;
-
Achieved full year 2018 guidance for revenue, Adjusted EBITDA and
Adjusted Earnings per Share.
IFRS 15 – Revenue Recognition: Results for the fourth quarter and fiscal
year 2018 reflect the impact of the application of IFRS 15. As a result,
certain items previously included in costs of sales are now classified
as a reduction of revenue. Application of this accounting policy reduced
fourth quarter 2018 revenue by $3.6 million and reduced fiscal year 2018
revenue by $13.3 million. As the Company’s 2018 Guidance did not reflect
the impact of this classification change, revenue is presented excluding
the new revenue recognition accounting impact to improve comparability
with Guidance and prior period results. The Company has provided a table
which details the impact this classification change has had on revenue
by quarter throughout 2018 (refer to “Summary of Consolidated
Quarterly Results” below and within the MD&A). There is no impact on
earnings from operations, Adjusted EBITDA or net income as a result of
the application of IFRS 15. Results for the year ended December 31, 2018
are presented under the new guidance, while prior year results have not
been adjusted and continue to be reported in accordance with historical
accounting guidance.
“We finished 2018 on a strong note with a record level of performance,
reporting 22% revenue growth during the fourth quarter excluding the
IFRS 15 revenue recognition impact and met each of our 2018 guidance
metrics. During the quarter and full year, we saw tremendous strength in
our core Jamieson brand, both domestically and internationally, and
robust growth in the Strategic Partners segment of the business,” said
Mark Hornick, President and Chief Executive Officer of Jamieson
Wellness. “During the fourth quarter, revenue in the branded segment was
12% higher than the previous year driven by a very strong 16% growth in
the Jamieson brand domestically and 26% growth internationally. We have
now implemented new leadership and structural improvements in our
Specialty Brands division to improve performance. We expect Specialty
Brands sales to return to growth in the second half of 2019. As we enter
a new year, we remain confident in our Company-wide growth strategies
and ability to achieve our strategic goals.”
Declaration of Fourth Quarter Dividend
On February 26, 2019, the board of directors declared a cash dividend
for the fourth quarter of 2018 of $0.09 per common share, or
approximately $3.4 million in the aggregate. The dividend will be paid
on March 15, 2019 to all common shareholders of record at the close of
business on March 7, 2019. The Company has designated this dividend as
an “eligible dividend” for the purposes of the Income Tax Act (Canada).
Fourth Quarter 2018 Results
Revenue increased 18%, or $14.8 million, to $99.1 million in Q4 2018 and
grew 22% to $102.8 million excluding the impact of the new revenue
recognition accounting change. Jamieson Brands revenues increased by
$7.8 million or 12% excluding the new revenue recognition accounting
impact of $3.6 million and Strategic Partners revenues increased by
$10.7 million or by 57%, all compared to the prior year period.
On a normalized basis, revenue growth in the Jamieson Brands segment was
driven by higher domestic Jamieson sales of $7.3 million and
international growth of $1.9 million, partially offset by lower volumes
on Specialty Brands (formerly referred to as “Health Foods” including
Body Plus and LVHS) of $1.4 million. Domestic Jamieson sales were 16%
higher driven by increased volumes from consumer demand, the February
price increase, innovations, and timing. International sales increased
by 26% versus the fourth quarter of 2017, led by growth in Asia, Europe
and the Middle East, while Specialty Brands volumes decreased by 11%. In
the fourth quarter of 2018 the Company implemented improvement
initiatives for its Specialty Brands division surrounding culture,
customer and consumer. As the quarter progressed these initiatives began
to take effect and revenue has improved on a month-over-month basis.
Specialty Brands represent 15% of consolidated revenues and is expected
to deliver approximately 1% of total Company long-term annual growth.
The Strategic Partners revenue increase was primarily driven by new
contracts and increased shipments due to strong demand for customers’
branded products. Fourth quarter revenue was also impacted by the raw
material delays from the third quarter of 2018, which led to a shift in
production and delivery into the fourth quarter of 2018.
Gross profit increased 14%, or $4.3 million, to $35.2 million during the
fourth quarter of 2018. Gross margin decreased to 35.5% from 36.6%,
primarily reflecting the higher proportion of Strategic Partners revenue
during the quarter compared to the prior year and the new revenue
recognition accounting impact.
SG&A expenses increased by 18%, or $2.6 million, to $16.9 million during
the fourth quarter of 2018. Excluding the $2.1 million in non-recurring
costs related mainly to business integration, new international and
e-commerce developments and other non-recurring costs, SG&A expenses
were $0.5 million higher than the prior year period reflecting the
reclassification of $0.4 million in fixed fee trade costs from Cost of
Goods sold.
Earnings from operations increased 15%, or $2.2 million, to
$17.1 million and operating margin decreased 50 basis points to 17.2% in
the fourth quarter of 2018. On a normalized basis, adjusting for the
non-recurring costs noted above, as well as the impact of share-based
compensation related to the accelerated vesting in the prior year
period, operating margin would have been 19.4% compared to 18.9% in the
prior year period.
Interest expense and other financing costs increased by $0.3 million to
$2.4 million in the fourth quarter of 2018 due to recent increases in
benchmark interest rates.
Net income for the fourth quarter of 2018 was $10.0 million compared to
$3.7 million in the fourth quarter of 2017. Adjusted Net Income, which
excludes non-operating expenses, increased 25% to $12.2 million, or
$0.31 per fully diluted shares, in the fourth quarter of 2018 from $9.7
million, or $0.25 per fully diluted share, in the fourth quarter of 2017.
Adjusted Net Income for the fourth quarter of 2018 excludes costs
primarily related to the integration of the LVHS business with Body
Plus, including the closure of two west coast distribution facilities
and the consolidation of supply chain activities, international market
expansion costs, other non-recurring items and the related tax effects.
Adjusted Net Income for the fourth quarter of 2017 excludes costs
associated with public offerings, acquisitions, restructuring
activities, foreign exchange losses and the related tax effects. A
detailed reconciliation of reported net income to non-IFRS Adjusted Net
Income is included in the tables accompanying this release under the
heading Non-IFRS Financial Measures.
Adjusted EBITDA increased 22% to $22.9 million in the fourth quarter of
2018 and Adjusted EBITDA margin increased to 23.1% from 22.4% in 2017.
Balance Sheet & Cash Flow
The Company generated $22.2 million of cash from operations during the
fourth quarter of 2018 compared to $17.2 million for the same period in
the prior year. The Company’s cash at December 31, 2018 was $12.4
million compared to $4.8 million on December 31, 2017. On November 20,
2018, the Company declared a quarterly dividend of $0.09 per common
share to holders of record as of November 30, 2018 and paid such
dividend on December 14, 2018. The dividend payment was approximately
$3.4 million in the aggregate.
|
|
|
|
|
|
|
|
|
Three months ended
|
|
|
|
|
|
|
December 31
|
|
|
|
|
($ in 000's, except as otherwise noted)
|
|
2018
|
|
|
2017
|
|
|
$ Change
|
|
|
% Change
|
|
|
|
|
|
|
|
|
|
|
Cash, beginning of period
|
|
2,815
|
|
|
1,196
|
|
|
1,619
|
|
|
135.4
|
%
|
Cash flows from (used in):
|
|
|
|
|
|
|
|
|
Operating activities
|
|
22,233
|
|
|
17,194
|
|
|
5,039
|
|
|
29.3
|
%
|
Investing activities
|
|
(4,611
|
)
|
|
(2,056
|
)
|
|
(2,555
|
)
|
|
(124.3
|
%)
|
Financing activities
|
|
(7,992
|
)
|
|
(11,501
|
)
|
|
3,509
|
|
|
30.5
|
%
|
Cash, end of period
|
|
12,445
|
|
|
4,833
|
|
|
7,612
|
|
|
157.5
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Initial 2019 Outlook
The Company is establishing its initial outlook for fiscal 2019 and
anticipates generating net revenue in a range of $336.0 to $348.0
million, representing growth of 5% to 9% over $319.8 million. Excluding
the new revenue recognition accounting impact, the Company’s net revenue
expectation would have been in a range of $350.0 million -
$362.0 million. The Company anticipates Adjusted EBITDA in a range of
$73.0 to $76.0 million and Adjusted Diluted Earnings per Share in a
range of $0.90 to $0.95.
This outlook reflects IFRS 15 revenue recognition accounting and the
following assumptions:
-
Jamieson Brands segment growth of 5%-9%, including:
-
3% to 5% growth of the Jamieson brand domestically
-
25% to 35% international growth and
-
Specialty Brands growth of 1% to 5%
-
Strategic Partners segment growth of 5% to 8%
-
Normalized SG&A increases of 11% to 15% to support international
market growth and e-commerce initiatives, among other costs
-
Increased depreciation expense reflecting higher capital expenditures
to support capacity expansions and the capitalization of operating
leases with the implementation of IFRS 16
-
A forecasted CAD/USD exchange rate of $1.33
-
Interest expense of $9.0 million to $9.5 million, based on interest
rates ranging between 4.5% to 5.5%
-
Income tax rate of approximately 28%
-
A fully diluted share count of approximately 40.0 million shares.
Consolidated Financial Statements and Management’s Discussion and
Analysis
The Company’s audited consolidated annual financial statements and
accompanying notes as at and for the three and twelve months ended
December 31, 2018 and related management’s discussion and analysis of
financial condition and results of operations (“MD&A”) are available
under the Company’s profile on SEDAR at www.sedar.com
and on the Investor Relations section of the Company’s website at https://investors.jamiesonwellness.com.
Conference Call
Management will host a conference call to discuss the Company’s fourth
quarter and full year 2018 results at 5:00 p.m. ET on February 27, 2019.
The call can be accessed live over the telephone by dialing
1-877-425-9470 from Canada and the U.S. or 1-201-389-0878 from
international locations. A replay will be available shortly after the
call and can be accessed by dialing 1-844-512-2921 from Canada and the
U.S. or 1-412-317-6671 from international locations. The passcode for
the replay is 13686518 and it will be available until Wednesday, March
13, 2019.
Interested parties may listen to a simultaneous webcast of the
conference call by logging on via the Investor Relations section of the
Company’s website at https://investors.jamiesonwellness.com
or directly at http://public.viavid.com/index.php?id=132840.
A replay of the webcast will be available for approximately 30 days
following the call.
About Jamieson Wellness
Jamieson Wellness is dedicated to improving the world’s health and
wellness with its portfolio of innovative natural health brands.
Established in 1922, Jamieson is the Company’s heritage brand and
Canada’s #1 consumer health brand. Jamieson Wellness manufactures and
markets sports nutrition products and specialty supplements under its Progressive,
Precision and Iron Vegan brands. The Company also markets
products by Lorna Vanderhaeghe Health Solutions (LVHS), the #1
women’s natural health focused brand in Canada. For more information
please visit jamiesonwellness.com.
Jamieson Wellness’ head office is located at 1 Adelaide Street East,
Toronto, Ontario, Canada.
Forward-Looking Information
This press release may contain forward-looking information within the
meaning of applicable securities legislation. Such information includes,
but is not limited to, statements related to the Company’s anticipated
growth opportunities and its outlook for its 2019 revenue, Adjusted
EBITDA and Adjusted Diluted Earnings per Share. Words such as “expect,”
“anticipate,” “intend,” “attempt,” “may,” “plan,” “will”, “can”,
“believe,” “seek,” “estimate,” and variations of such words and similar
expressions are intended to identify such forward-looking information.
This information reflects the Company’s current expectations regarding
future events. Forward-looking information is based on a number of
assumptions and is subject to a number of risks and uncertainties, many
of which are beyond the Company’s control that could cause actual
results and events to differ materially from those that are disclosed in
or implied by such forward-looking information. Such risks and
uncertainties include, but are not limited to, the factors discussed
under “Risk Factors” in the Company’s final prospectus (“Prospectus”)
dated June 29, 2017 in respect of its initial public offering, as
modified by the disclosure under the “Risk Factors” section in the
Company’s MD&A filed February 27, 2019. This information is based on the
Company’s reasonable assumptions and beliefs in light of the information
currently available to it and the statements are made as of the date of
this press release. The Company does not undertake any obligation to
update such forward-looking information, whether as a result of new
information, future events or otherwise, except as expressly required by
applicable law or regulatory authority.
We caution that the list of risk factors and uncertainties is not
exhaustive and other factors could also adversely affect the Company’s
results. Readers are urged to consider the risks, uncertainties and
assumptions associated with these statements carefully in evaluating the
forward-looking information and are cautioned not to place undue
reliance on such information. See “Forward-looking Information”, “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations — Outlook” in the Company’s MD&A for
a discussion of the uncertainties, risks and assumptions associated with
these statements.
|
|
|
|
|
Jamieson Wellness Inc.
|
Consolidated Statements of Operations
|
In thousands of Canadian dollars, except share and per share
amounts
|
|
|
|
|
|
|
|
Three months ended
|
|
For the year ended
|
|
|
December 31
|
|
December 31
|
|
|
2018
|
|
|
2017
|
|
|
2018
|
|
|
2017
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
99,145
|
|
|
84,318
|
|
|
319,776
|
|
|
300,619
|
|
Cost of sales
|
|
63,906
|
|
|
53,421
|
|
|
204,358
|
|
|
195,770
|
|
Gross profit
|
|
35,239
|
|
|
30,897
|
|
|
115,418
|
|
|
104,849
|
|
|
|
|
|
|
|
|
|
|
Gross profit margin
|
|
35.5
|
%
|
|
36.6
|
%
|
|
36.1
|
%
|
|
34.9
|
%
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative expenses
|
|
16,859
|
|
|
14,252
|
|
|
62,261
|
|
|
53,589
|
|
Share-based compensation
|
|
1,278
|
|
|
1,712
|
|
|
3,067
|
|
|
6,325
|
|
Earnings from operations
|
|
17,102
|
|
|
14,933
|
|
|
50,090
|
|
|
44,935
|
|
|
|
|
|
|
|
|
|
|
Operating margin
|
|
17.2
|
%
|
|
17.7
|
%
|
|
15.7
|
%
|
|
14.9
|
%
|
|
|
|
|
|
|
|
|
|
Foreign exchange loss
|
|
89
|
|
|
116
|
|
|
608
|
|
|
331
|
|
Termination benefits and related costs
|
|
129
|
|
|
1,633
|
|
|
2,933
|
|
|
4,132
|
|
Public offering costs
|
|
-
|
|
|
1,200
|
|
|
-
|
|
|
10,720
|
|
Acquisition costs
|
|
-
|
|
|
-
|
|
|
-
|
|
|
2,444
|
|
Other expenses
|
|
64
|
|
|
2,981
|
|
|
298
|
|
|
9,410
|
|
Preferred share accretion
|
|
-
|
|
|
-
|
|
|
-
|
|
|
28,796
|
|
Interest expense and other financing costs
|
|
2,390
|
|
|
2,140
|
|
|
9,000
|
|
|
4,733
|
|
Income (loss) before income taxes
|
|
14,430
|
|
|
6,863
|
|
|
37,251
|
|
|
(15,631
|
)
|
Provision for income taxes
|
|
4,384
|
|
|
3,130
|
|
|
10,578
|
|
|
8,156
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
10,046
|
|
|
3,733
|
|
|
26,673
|
|
|
(23,787
|
)
|
Adjusted net income
|
|
12,217
|
|
|
9,749
|
|
|
33,733
|
|
|
27,582
|
|
|
|
|
|
|
|
|
|
|
EBITDA
|
|
19,220
|
|
|
11,194
|
|
|
55,297
|
|
|
26,400
|
|
Adjusted EBITDA
|
|
22,933
|
|
|
18,848
|
|
|
67,628
|
|
|
61,477
|
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA margin
|
|
23.1
|
%
|
|
22.4
|
%
|
|
21.1
|
%
|
|
20.5
|
%
|
|
|
|
|
|
|
|
|
|
Weighted average number of shares
|
|
|
|
|
|
|
|
|
Basic
|
|
38,166,594
|
|
|
37,729,359
|
|
|
38,009,443
|
|
|
18,669,758
|
|
Diluted
|
|
39,707,979
|
|
|
39,639,122
|
|
|
39,531,078
|
|
|
18,669,758
|
|
Adjusted Diluted
|
|
39,707,979
|
|
|
39,639,122
|
|
|
39,707,979
|
|
|
39,639,122
|
|
|
|
|
|
|
|
|
|
|
Earnings per share attributable to common shareholders:
|
|
|
|
|
|
|
|
|
Basic, earnings (loss) per share
|
|
0.26
|
|
|
0.10
|
|
|
0.70
|
|
|
(1.79
|
)
|
Diluted, earnings (loss) per share
|
|
0.25
|
|
|
0.09
|
|
|
0.67
|
|
|
(1.79
|
)
|
Adjusted Diluted, earnings per share
|
|
0.31
|
|
|
0.25
|
|
|
0.85
|
|
|
0.70
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jamieson Wellness Inc.
|
Consolidated Statements of Financial Position
|
In thousands of Canadian dollars
|
|
|
|
|
|
|
|
December 31,
2018
|
|
December 31,
2017
|
Assets
|
|
|
|
|
Current assets
|
|
|
|
|
Cash
|
|
12,445
|
|
|
4,833
|
|
Accounts receivable
|
|
82,227
|
|
|
71,996
|
|
Inventories
|
|
72,079
|
|
|
59,080
|
|
Derivatives
|
|
3,124
|
|
|
-
|
|
Prepaid expenses and other current assets
|
|
2,163
|
|
|
1,507
|
|
|
|
172,038
|
|
|
137,416
|
|
Non-current assets
|
|
|
|
|
Property, plant and equipment
|
|
50,234
|
|
|
45,173
|
|
Goodwill
|
|
122,975
|
|
|
122,975
|
|
Intangible assets
|
|
201,371
|
|
|
204,264
|
|
Deferred income tax
|
|
2,403
|
|
|
2,727
|
|
Total assets
|
|
549,021
|
|
|
512,555
|
|
|
|
|
|
|
Liabilities
|
|
|
|
|
Current liabilities
|
|
|
|
|
Accounts payable and accrued liabilities
|
|
83,481
|
|
|
66,621
|
|
Income taxes payable
|
|
4,454
|
|
|
4,267
|
|
Derivatives
|
|
-
|
|
|
1,081
|
|
Current portion of long-term debt
|
|
14,625
|
|
|
9,750
|
|
|
|
102,560
|
|
|
81,719
|
|
Long-term liabilities
|
|
|
|
|
Long-term debt
|
|
151,287
|
|
|
153,459
|
|
Post-retirement benefits
|
|
2,923
|
|
|
4,856
|
|
Deferred income tax
|
|
51,529
|
|
|
51,697
|
|
Total liabilities
|
|
308,299
|
|
|
291,731
|
|
|
|
|
|
|
Shareholders' equity
|
|
|
|
|
Share capital
|
|
239,404
|
|
|
234,908
|
|
Contributed surplus
|
|
9,037
|
|
|
7,437
|
|
Deficit
|
|
(10,670
|
)
|
|
(19,486
|
)
|
Accumulated other comprehensive income (loss)
|
|
2,951
|
|
|
(2,035
|
)
|
Total shareholders' equity
|
|
240,722
|
|
|
220,824
|
|
Total liabilities and shareholders' equity
|
|
549,021
|
|
|
512,555
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jamieson Wellness Inc.
|
Segment Information
|
In thousands of Canadian dollars, except as otherwise noted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jamieson Brands
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
December 31
|
|
|
|
|
|
|
|
2018
|
|
2017
|
|
$ Change
|
|
% Change
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
69,715
|
|
65,545
|
|
4,170
|
|
6.4%
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
31,079
|
|
27,107
|
|
3,972
|
|
14.7%
|
|
Gross profit margin
|
|
44.6%
|
|
41.4%
|
|
-
|
|
3.2%
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative expenses
|
|
15,324
|
|
12,663
|
|
2,661
|
|
21.0%
|
|
|
|
|
|
|
|
|
|
|
|
Share-based compensation
|
|
1,278
|
|
1,712
|
|
(434)
|
|
(25.4%)
|
|
|
|
|
|
|
|
|
|
|
|
Earnings from operations
|
|
14,477
|
|
12,732
|
|
1,745
|
|
13.7%
|
|
Operating margin
|
|
20.8%
|
|
19.4%
|
|
-
|
|
1.4%
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA
|
|
19,742
|
|
16,308
|
|
3,434
|
|
21.1%
|
|
Adjusted EBITDA margin
|
|
28.3%
|
|
24.9%
|
|
-
|
|
3.4%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Strategic Partners
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
December 31
|
|
|
|
|
|
|
|
2018
|
|
2017
|
|
$ Change
|
|
% Change
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
29,430
|
|
18,773
|
|
10,657
|
|
56.8%
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
4,160
|
|
3,790
|
|
370
|
|
9.8%
|
|
Gross profit margin
|
|
14.1%
|
|
20.2%
|
|
-
|
|
(6.1%)
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative expenses
|
|
1,535
|
|
1,589
|
|
(54)
|
|
(3.4%)
|
|
|
|
|
|
|
|
|
|
|
|
Earnings from operations
|
|
2,625
|
|
2,201
|
|
424
|
|
19.3%
|
|
Operating margin
|
|
8.9%
|
|
11.7%
|
|
-
|
|
(2.8%)
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA
|
|
3,191
|
|
2,540
|
|
651
|
|
25.6%
|
|
Adjusted EBITDA margin
|
|
10.8%
|
|
13.5%
|
|
-
|
|
(2.7%)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jamieson Wellness Inc.
|
Segment Information
|
In thousands of Canadian dollars, except as otherwise noted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jamieson Brands
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the year ended
December 31
|
|
|
|
|
|
|
|
2018
|
|
2017
|
|
$ Change
|
|
% Change
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
243,772
|
|
237,001
|
|
6,771
|
|
2.9%
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
104,115
|
|
91,559
|
|
12,556
|
|
13.7%
|
|
Gross profit margin
|
|
42.7%
|
|
38.6%
|
|
-
|
|
4.1%
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative expenses
|
|
55,877
|
|
47,639
|
|
8,238
|
|
17.3%
|
|
|
|
|
|
|
|
|
|
|
|
Share-based compensation
|
|
3,067
|
|
6,325
|
|
(3,258)
|
|
(51.5%)
|
|
|
|
|
|
|
|
|
|
|
|
Earnings from operations
|
|
45,171
|
|
37,595
|
|
7,576
|
|
20.2%
|
|
Operating margin
|
|
18.5%
|
|
15.9%
|
|
-
|
|
2.6%
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA
|
|
60,173
|
|
52,834
|
|
7,339
|
|
13.9%
|
|
Adjusted EBITDA margin
|
|
24.7%
|
|
22.3%
|
|
-
|
|
2.4%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Strategic Partners
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the year ended
December 31
|
|
|
|
|
|
|
|
2018
|
|
2017
|
|
$ Change
|
|
% Change
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
76,004
|
|
63,618
|
|
12,386
|
|
19.5%
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
11,303
|
|
13,290
|
|
(1,987)
|
|
(15.0%)
|
|
Gross profit margin
|
|
14.9%
|
|
20.9%
|
|
-
|
|
(6.0%)
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative expenses
|
|
6,384
|
|
5,950
|
|
434
|
|
7.3%
|
|
|
|
|
|
|
|
|
|
|
|
Earnings from operations
|
|
4,919
|
|
7,340
|
|
(2,421)
|
|
(33.0%)
|
|
Operating margin
|
|
6.5%
|
|
11.5%
|
|
-
|
|
(5.0%)
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA
|
|
7,455
|
|
8,643
|
|
(1,188)
|
|
(13.7%)
|
|
Adjusted EBITDA margin
|
|
9.8%
|
|
13.6%
|
|
-
|
|
(3.8%)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Summary of Consolidated Quarterly Results
The following is a summary of selected consolidated financial
information for each of the eight most recently completed quarters
prepared in accordance with IFRS. As of January 1, 2018, the Company has
adopted IFRS 15 using the modified retrospective method. The adoption of
IFRS 15 resulted in a reclassification in the presentation of certain
consideration paid to customers, which was made to the annual
consolidated financial statements for the year ended December 31, 2018.
Management has revised all prior quarters in 2018 for this
reclassification in the below summary.
|
|
2018
|
|
|
2017
|
|
($ in 000's, except per share amounts)
|
|
Q4
|
|
Q3 *
|
|
Q2 *
|
|
Q1 *
|
|
|
Q4
|
|
Q3
|
|
Q2
|
|
Q1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue by segment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jamieson Brands
|
|
69,715
|
|
61,787
|
|
55,701
|
|
56,569
|
|
|
65,545
|
|
61,889
|
|
|
56,647
|
|
|
52,920
|
|
Strategic Partners
|
|
29,430
|
|
17,872
|
|
18,492
|
|
10,210
|
|
|
18,773
|
|
18,256
|
|
|
14,608
|
|
|
11,981
|
|
Total revenue
|
|
99,145
|
|
79,659
|
|
74,193
|
|
66,779
|
|
|
84,318
|
|
80,145
|
|
|
71,255
|
|
|
64,901
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings from operations
|
|
17,102
|
|
12,690
|
|
10,172
|
|
10,126
|
|
|
14,933
|
|
11,281
|
|
|
10,699
|
|
|
8,022
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
10,046
|
|
7,213
|
|
4,788
|
|
4,626
|
|
|
3,733
|
|
1,089
|
|
|
(6,958
|
)
|
|
(21,651
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted net income
|
|
12,217
|
|
8,853
|
|
6,903
|
|
5,760
|
|
|
9,749
|
|
7,793
|
|
|
7,870
|
|
|
2,170
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EBITDA
|
|
19,220
|
|
14,771
|
|
10,967
|
|
10,339
|
|
|
11,194
|
|
8,346
|
|
|
3,255
|
|
|
3,605
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA
|
|
22,933
|
|
17,856
|
|
14,153
|
|
12,686
|
|
|
18,848
|
|
16,134
|
|
|
15,071
|
|
|
11,424
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic, earnings (loss) per share
|
|
0.26
|
|
0.19
|
|
0.13
|
|
0.12
|
|
|
0.10
|
|
(0.24
|
)
|
|
(13.37
|
)
|
|
(41.62
|
)
|
Diluted, earnings (loss) per share
|
|
0.25
|
|
0.18
|
|
0.12
|
|
0.12
|
|
|
0.09
|
|
(0.24
|
)
|
|
(13.37
|
)
|
|
(41.62
|
)
|
Adjusted Diluted, earnings per share
|
|
0.31
|
|
0.22
|
|
0.17
|
|
0.15
|
|
|
0.25
|
|
0.20
|
|
|
0.20
|
|
|
0.05
|
|
* Revised based on IFRS 15 revenue reclassification
Results for the year ended December 31, 2018 are presented under the new
guidance, while prior year results have not been adjusted and continue
to be reported in accordance with historical accounting guidance. If the
IFRS 15 revenue recognition impact was applied retrospectively to 2017,
total revenue for the year would have been $286.1 million compared to
total revenue in 2018 of $319.8 million, representing year-over-year
growth of 11.8%.
Non-IFRS Financial Measures
This press release makes reference to certain non-IFRS measures.
Management uses these non-IFRS financial measures for purposes of
comparison to prior periods and development of future projections and
earnings growth prospects. This information is also used by management
to measure the profitability of ongoing operations and in analyzing the
Company’s business performance and trends. These measures are not
recognized measures under IFRS, do not have a standardized meaning
prescribed by IFRS and are therefore unlikely to be comparable to
similar measures presented by other companies. Rather, these measures
are provided as additional information to complement those IFRS measures
by providing further understanding of the Company’s results of
operations from management’s perspective. Accordingly, they should not
be considered in isolation nor as a substitute for analysis of the
Company’s financial information reported under IFRS. We use non-IFRS
measures, including “gross profit”, “gross profit margin”, “operating
margin” “EBITDA”, “Adjusted EBITDA”, “Adjusted EBITDA margin”, “Adjusted
Net Income” and “Adjusted Diluted Earnings per Share” to provide
supplemental measures of the Company’s operating performance and thus
highlight trends in the Company’s core business that may not otherwise
be apparent when relying solely on IFRS financial measures. Management
also uses non-IFRS measures in order to prepare annual operating budgets
and to determine components of management compensation. Definitions of
non-IFRS measures can be found in our MD&A.
|
|
|
|
|
Reconciliation of Adjusted Net Income
|
|
|
|
|
|
|
|
Three months ended
|
|
For the year ended
|
($ in 000's)
|
|
December 31
|
|
December 31
|
|
|
2018
|
|
|
2017
|
|
|
2018
|
|
|
2017
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
10,046
|
|
|
3,733
|
|
|
26,673
|
|
|
(23,787
|
)
|
Adjustments to net income (loss):
|
|
|
|
|
|
|
|
|
Share-based compensation
|
|
383
|
|
|
978
|
|
|
535
|
|
|
4,171
|
|
Amortization of fair value adjustments
|
|
-
|
|
|
-
|
|
|
-
|
|
|
1,694
|
|
Amortization of deferred financing fee
|
|
-
|
|
|
-
|
|
|
-
|
|
|
3,078
|
|
Foreign exchange loss
|
|
89
|
|
|
116
|
|
|
608
|
|
|
331
|
|
Termination benefits and related costs
|
|
129
|
|
|
1,633
|
|
|
2,933
|
|
|
4,132
|
|
Acquisition costs
|
|
-
|
|
|
-
|
|
|
-
|
|
|
2,444
|
|
Purchase consideration accounted for as compensation expense
|
|
-
|
|
|
2,521
|
|
|
(1,066
|
)
|
|
8,427
|
|
Public offering costs
|
|
-
|
|
|
1,200
|
|
|
-
|
|
|
10,720
|
|
Net interest forgiveness
|
|
-
|
|
|
-
|
|
|
-
|
|
|
(11,001
|
)
|
Preferred share accretion
|
|
-
|
|
|
-
|
|
|
-
|
|
|
28,796
|
|
International market expansion
|
|
669
|
|
|
-
|
|
|
929
|
|
|
-
|
|
Non-recurring business integration
|
|
844
|
|
|
-
|
|
|
4,142
|
|
|
-
|
|
Other
|
|
704
|
|
|
472
|
|
|
1,718
|
|
|
1,004
|
|
Related tax effects
|
|
(647
|
)
|
|
(904
|
)
|
|
(2,739
|
)
|
|
(2,427
|
)
|
Adjusted net income
|
|
12,217
|
|
|
9,749
|
|
|
33,733
|
|
|
27,582
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of EBITDA and Adjusted EBITDA
|
|
|
|
|
|
|
|
Three months ended
|
|
For the year ended
|
|
|
December 31
|
|
December 31
|
|
|
2018
|
|
2017
|
|
2018
|
|
|
2017
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
10,046
|
|
3,733
|
|
26,673
|
|
|
(23,787
|
)
|
Add:
|
|
|
|
|
|
|
|
|
Provision for income taxes
|
|
4,384
|
|
3,130
|
|
10,578
|
|
|
8,156
|
|
Interest expense and other financing costs
|
|
2,390
|
|
2,140
|
|
9,000
|
|
|
4,733
|
|
Preferred share accretion
|
|
-
|
|
-
|
|
-
|
|
|
28,796
|
|
Depreciation of property, plant, and equipment
|
|
1,532
|
|
1,336
|
|
5,551
|
|
|
5,106
|
|
Amortization of intangible assets
|
|
868
|
|
855
|
|
3,495
|
|
|
3,396
|
|
|
|
|
|
|
|
|
|
|
Earnings before interest, taxes, depreciation, and amortization
(EBITDA)
|
|
19,220
|
|
11,194
|
|
55,297
|
|
|
26,400
|
|
Add EBITDA adjustments:
|
|
|
|
|
|
|
|
|
Share-based compensation
|
|
1,278
|
|
1,712
|
|
3,067
|
|
|
6,325
|
|
Amortization of fair value adjustments
|
|
-
|
|
-
|
|
-
|
|
|
1,694
|
|
Foreign exchange loss
|
|
89
|
|
116
|
|
608
|
|
|
331
|
|
Termination benefits and related costs
|
|
129
|
|
1,633
|
|
2,933
|
|
|
4,132
|
|
Acquisition costs
|
|
-
|
|
-
|
|
-
|
|
|
2,444
|
|
Purchase consideration accounted for as compensation expense
|
|
-
|
|
2,521
|
|
(1,066
|
)
|
|
8,427
|
|
Public offering costs
|
|
-
|
|
1,200
|
|
-
|
|
|
10,720
|
|
International market expansion
|
|
669
|
|
-
|
|
929
|
|
|
-
|
|
Non-recurring business integration
|
|
844
|
|
-
|
|
4,142
|
|
|
-
|
|
Other
|
|
704
|
|
472
|
|
1,718
|
|
|
1,004
|
|
Adjusted EBITDA
|
|
22,933
|
|
18,848
|
|
67,628
|
|
|
61,477
|
|
View source version on businesswire.com:
https://www.businesswire.com/news/home/20190227005948/en/
Investor Relations
Jamieson Wellness
Ruth Winker
416-705-5437
rwinker@jamiesonlabs.com
Source: Jamieson Wellness Inc.